Adam Schayowitz Sells 13,832 Zymeworks Shares at $25.85 Each, Totaling $357,557

Adam Schayowitz, EVP, Head of R&D at Zymeworks Inc. (ticker ZYME), sold 13,832 shares on October 10, 2026, at $25.85 per share, totaling $357,557.

Who is Adam Schayowitz and What is His Real Role at Zymeworks?

Adam Schayowitz holds the position of Executive Vice President (EVP) and Chief Research & Development (R&D) Officer within Zymeworks, a publicly traded biopharmaceutical company. As EVP, he is part of the senior management team and plays a key role in strategic decisions regarding the drug pipeline, research partnerships, and investment priorities. His role as R&D head grants him direct access to confidential information related to clinical trials, scientific results, and future development projects. This data is considered "material non-public information" under financial regulations, as it could influence market perception of the stock's future value.

Being both a member of the executive leadership and head of R&D places Adam Schayowitz among the most informed insiders at the company. This dual role implies that he is regularly briefed on technological advancements, project funding decisions, and potential regulatory hurdles. Therefore, any transaction he makes regarding Zymeworks shares is subject to SEC oversight and must be promptly communicated to investors via Form 4.

Transaction Details: 13,832 Shares at $25.85 Each

The Form 4 filed on October 10, 2026, indicates that Adam Schayowitz sold 13,832 Zymeworks shares. The per-share price was $25.85, resulting in a total transaction value of $357,557. It is crucial to distinguish between the per-share price ($25.85) and the total value ($357,557) to avoid confusion in data interpretation. No other share movements are mentioned in the same filing, suggesting that this sale represents the entirety of the transaction reported on that date.

Why Insiders Sell Their Shares – Possible Reasons

Share sales by insiders can stem from several motivations, not necessarily linked to the company's future performance. First, portfolio diversification is a common reason: an executive might want to reduce their exposure to a single stock to mitigate overall risk. Second, tax planning may encourage a sale to take advantage of a favorable tax year or offset other taxable gains. Third, personal liquidity needs, such as purchasing real estate or funding education, could also explain a share sale. Lastly, while the sale might be perceived as a bearish signal, it's possible that the insider has no additional negative information; they are simply monetizing a portion of their stake for personal reasons or wealth management. Without further information, no definitive conclusion can be drawn regarding ZYME's future stock direction.

How Individual Investors Track Form 4 Filings

Form 4 filings are made public on the SEC EDGAR platform, where they are freely accessible to all market participants. Individual investors can view these documents by visiting the SEC website and searching for the ZYME ticker or the insider's name. Free tools like "Finviz," "OpenInsider," or online brokerage services offer aggregated data and alerts on Form 4 filings, making it easier to monitor insider movements. However, it's important to note that Form 4 information is limited to the reported transaction; it provides no insight into long-term intentions or future company performance. Investors should combine this data with broader fundamental and technical analysis before making buy or sell decisions.

In summary, Adam Schayowitz's sale of 13,832 Zymeworks shares, totaling $357,557, as reported via Form 4, complies with SEC requirements mandating disclosure within two business days. While the bearish signal may attract attention, the potential reasons for the sale are varied and do not definitively predict the stock's future trajectory. Individual investors have free tools to monitor these filings but should integrate this information into a comprehensive analytical approach to make informed decisions.